

Kenji Ishitsuka

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5760403/publications.pdf>

Version: 2024-02-01

157
papers

6,176
citations

94433

37
h-index

71685

76
g-index

168
all docs

168
docs citations

168
times ranked

6171
citing authors

#	ARTICLE	IF	CITATIONS
1	Defucosylated Anti-CCR4 Monoclonal Antibody (KW-0761) for Relapsed Adult T-Cell Leukemia-Lymphoma: A Multicenter Phase II Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 837-842.	1.6	581
2	Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. <i>Blood</i> , 2006, 107, 4053-4062.	1.4	398
3	Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. <i>Lancet Oncology</i> , The, 2014, 15, e517-e526.	10.7	282
4	Bortezomib Mediates Antiangiogenesis in Multiple Myeloma via Direct and Indirect Effects on Endothelial Cells. <i>Cancer Research</i> , 2006, 66, 184-191.	0.9	266
5	Treatment and survival among 1594 patients with ATL. <i>Blood</i> , 2015, 126, 2570-2577.	1.4	244
6	Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study. <i>British Journal of Haematology</i> , 2015, 169, 672-682.	2.5	218
7	The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 19478-19483.	7.1	189
8	Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. <i>Blood</i> , 2004, 104, 4188-4193.	1.4	177
9	Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. <i>Blood</i> , 2005, 106, 1042-1047.	1.4	172
10	Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. <i>Blood</i> , 2005, 106, 1794-1800.	1.4	167
11	Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report. <i>Journal of Clinical Oncology</i> , 2019, 37, 677-687.	1.6	162
12	Prognostic Index for Acute- and Lymphoma-Type Adult T-Cell Leukemia/Lymphoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 1635-1640.	1.6	160
13	5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1718-1727.	4.1	154
14	VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. <i>Blood</i> , 2004, 104, 2886-2892.	1.4	147
15	MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. <i>Blood</i> , 2007, 110, 3744-3752.	1.4	144
16	JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. <i>Blood</i> , 2007, 110, 709-718.	1.4	139
17	MLN120B, a Novel Î²B Kinase Î² Inhibitor, Blocks Multiple Myeloma Cell Growth In vitro and In vivo. <i>Clinical Cancer Research</i> , 2006, 12, 5887-5894.	7.0	130
18	p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. <i>Oncogene</i> , 2004, 23, 8766-8776.	5.9	127

#	ARTICLE	IF	CITATIONS
19	Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications. <i>Cancer Research</i> , 2004, 64, 2846-2852.	0.9	126
20	Prognostic relevance of integrated genetic profiling in adult T-cell leukemia/lymphoma. <i>Blood</i> , 2018, 131, 215-225.	1.4	124
21	Transforming Growth Factor β 2 Receptor I Kinase Inhibitor Down-Regulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment. <i>Clinical Cancer Research</i> , 2004, 10, 7540-7546.	7.0	111
22	FTY720 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Drug Resistance. <i>Cancer Research</i> , 2005, 65, 7478-7484.	0.9	97
23	Caveolin-1 Is Required for Vascular Endothelial Growth Factor-Triggered Multiple Myeloma Cell Migration and Is Targeted by Bortezomib. <i>Cancer Research</i> , 2004, 64, 7500-7506.	0.9	86
24	Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A). <i>British Journal of Haematology</i> , 2014, 166, 739-748.	2.5	79
25	Treatment of adult T-cell leukemia/lymphoma: past, present, and future. <i>European Journal of Haematology</i> , 2008, 80, 185-196.	2.2	73
26	Inhibition by arsenic trioxide of human hepatoma cell growth. <i>Cancer Letters</i> , 2002, 183, 147-153.	7.2	68
27	Epidemiological and clinical features of adult T-cell leukemia-lymphoma in Japan, 2010-2011: A nationwide survey. <i>Cancer Science</i> , 2017, 108, 2478-2486.	3.9	63
28	Gene expression profiling of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly reveals alterations of characteristic oncogenetic pathways. <i>Cancer Science</i> , 2014, 105, 537-544.	3.9	61
29	Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. <i>Blood</i> , 2005, 105, 4470-4476.	1.4	59
30	Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway. <i>Oncogene</i> , 2005, 24, 5888-5896.	5.9	56
31	SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. <i>Blood</i> , 2005, 106, 706-712.	1.4	54
32	p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. <i>British Journal of Haematology</i> , 2008, 141, 598-606.	2.5	53
33	Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 1818-1823.	1.3	52
34	Arsenic trioxide inhibits growth of human T-cell leukaemia virus type I infected T-cell lines more effectively than retinoic acids. <i>British Journal of Haematology</i> , 1998, 103, 721-728.	2.5	49
35	BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth. <i>British Journal of Haematology</i> , 2007, 136, 414-423.	2.5	49
36	Whole-genome landscape of adult T-cell leukemia/lymphoma. <i>Blood</i> , 2022, 139, 967-982.	1.4	44

#	ARTICLE	IF	CITATIONS
37	Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)- β inhibitors. <i>Oncogene</i> , 2005, 24, 3121-3129.	5.9	43
38	Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma. <i>Blood</i> , 2017, 130, 39-47.	1.4	43
39	Prognosis of patients with adult T-cell leukemia/lymphoma in Japan: A nationwide hospital-based study. <i>Cancer Science</i> , 2020, 111, 4567-4580.	3.9	37
40	Targeting CD56 by the maytansinoid immunoconjugate IMGN901 (huN901-DM1): a potential therapeutic modality implication against natural killer/T cell malignancy. <i>British Journal of Haematology</i> , 2008, 141, 129-131.	2.5	34
41	Targeting Bcl-2 family proteins in adult T-cell leukemia/lymphoma: In vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737. <i>Cancer Letters</i> , 2012, 317, 218-225.	7.2	32
42	Establishment of a novel diagnostic test algorithm for human T-cell leukemia virus type 1 infection with line immunoassay replacement of western blotting: a collaborative study for performance evaluation of diagnostic assays in Japan. <i>Retrovirology</i> , 2020, 17, 26.	2.0	30
43	Follow-up of a randomised phase II study of chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: impact on allogeneic haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2019, 184, 479-483.	2.5	29
44	Arsenic Trioxide and the Growth of Human T-cell Leukemia Virus Type I Infected T-cell Lines. <i>Leukemia and Lymphoma</i> , 2000, 37, 649-655.	1.3	28
45	A phase II study of bortezomib in patients with relapsed or refractory aggressive adult T-cell leukemia/lymphoma. <i>Cancer Science</i> , 2015, 106, 1219-1223.	3.9	28
46	Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia-lymphoma in Japan: interim results of postmarketing all-case surveillance. <i>International Journal of Hematology</i> , 2017, 106, 522-532.	1.6	28
47	Treatment advances and prognosis for patients with adult T-cell leukemia-lymphoma. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2017, 57, 87-97.	0.8	26
48	Combination Chemotherapy (RCM Protocol: Response-Oriented Cyclic Multidrug Protocol) For the Acute or Lymphoma Type Adult T-cell Leukemia. <i>Leukemia and Lymphoma</i> , 1995, 18, 317-323.	1.3	25
49	Mogamulizumab for adult T-cell leukemia-lymphoma: a multicenter prospective observational study. <i>Blood Advances</i> , 2020, 4, 5133-5145.	5.2	25
50	Screening of promising chemotherapeutic candidates from plants against human adult T-cell leukemia/lymphoma (III). <i>Journal of Natural Medicines</i> , 2013, 67, 894-903.	2.3	23
51	Arsenic Trioxide Induces Apoptosis in HTLV-I Infected T-cell Lines and Fresh Adult T-cell Leukemia Cells Through CD95 or Tumor Necrosis Factor α Receptor Independent Caspase Activation. <i>Leukemia and Lymphoma</i> , 2002, 43, 1107-1114.	1.3	22
52	C-MYC and Its Main Ubiquitin Ligase, FBXW7, Influence Cell Proliferation and Prognosis in Adult T-cell Leukemia/Lymphoma. <i>American Journal of Surgical Pathology</i> , 2017, 41, 1139-1149.	3.7	22
53	Therapeutic potential of arsenic trioxide with or without interferon- γ for relapsed/refractory adult T-cell leukemia/lymphoma. <i>Haematologica</i> , 2007, 92, 719-720.	3.5	21
54	A patient with acute myeloid leukemia who developed fatal pneumonia caused by carbapenem-resistant <i>Bacillus cereus</i> . <i>Journal of Infection and Chemotherapy</i> , 2009, 15, 39-41.	1.7	21

#	ARTICLE	IF	CITATIONS
55	High expression of NAMPT in adult T-cell leukemia/lymphoma and anti-tumor activity of a NAMPT inhibitor. <i>European Journal of Pharmacology</i> , 2019, 865, 172738.	3.5	21
56	Smouldering adult T-cell leukaemia/lymphoma: a follow-up study in Kyushu. <i>British Journal of Haematology</i> , 2008, 143, 442-444.	2.5	20
57	Bone marrow necrosis in a patient with acute promyelocytic leukemia during re-induction therapy with arsenic trioxide. <i>European Journal of Haematology</i> , 2004, 72, 280-284.	2.2	18
58	In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells. <i>British Journal of Haematology</i> , 2006, 134, 37-44.	2.5	18
59	Screening of promising chemotherapeutic candidates against human adult T-cell leukemia/lymphoma from plants: active principles from <i>Physalis pruinosa</i> and structure-activity relationships with withanolides. <i>Journal of Natural Medicines</i> , 2011, 65, 559-567.	2.3	17
60	Safety and effectiveness of mogamulizumab in relapsed or refractory adult T-cell leukemia-lymphoma. <i>European Journal of Haematology</i> , 2019, 102, 407-415.	2.2	17
61	Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia/lymphoma. <i>Anticancer Research</i> , 2014, 34, 5287-94.	1.1	16
62	Clinical significance of cutaneous adverse reaction to mogamulizumab in relapsed or refractory adult T-cell leukaemia-lymphoma. <i>British Journal of Haematology</i> , 2018, 181, 539-542.	2.5	14
63	A retrospective analysis of haplo-identical HLA-mismatch hematopoietic transplantation without posttransplantation cyclophosphamide for GVHD prophylaxis in patients with adult T-cell leukemia-lymphoma. <i>Bone Marrow Transplantation</i> , 2019, 54, 1266-1274.	2.4	14
64	Epidemiology of adult T-cell leukemia-lymphoma in Japan: An updated analysis, 2012-2013. <i>Cancer Science</i> , 2021, 112, 4346-4354.	3.9	14
65	First-in-Human Study of the EZH1/2 Dual Inhibitor Valemetostat in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) - Updated Results Focusing on Adult T-Cell Leukemia-Lymphoma (ATL). <i>Blood</i> , 2019, 134, 4025-4025.	1.4	13
66	Colitis mimicking graft-versus-host disease during treatment with the anti-CCR4 monoclonal antibody, mogamulizumab. <i>International Journal of Hematology</i> , 2015, 102, 493-497.	1.6	12
67	High Expression of Intestinal Homing Receptor CD103 in Adult T-Cell Leukemia/Lymphoma, Similar to 2 Other CD8+ T-Cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2016, 40, 462-470.	3.7	12
68	Screening of promising chemotherapeutic candidates from plants against human adult T-cell leukemia/lymphoma (II): apoptosis of antiproliferative principle (24,25-dihydrowithanolide D) against ATL cell lines and structure-activity relationships with withanolides isolated from solanaceous plants. <i>Journal of Natural Medicines</i> , 2013, 67, 415-420.	2.3	11
69	Essential thrombocytosis attributed to JAK2-T875N germline mutation. <i>International Journal of Hematology</i> , 2019, 110, 584-590.	1.6	11
70	Randomized phase II study of mogamulizumab (KW-0761) plus VCAP-AMP-VECP (mLSG15) versus mLSG15 alone for newly diagnosed aggressive adult T-cell leukemia-lymphoma (ATL).. <i>Journal of Clinical Oncology</i> , 2013, 31, 8506-8506.	1.6	11
71	Evaluation of regional cerebral glucose metabolism in patients with malignant lymphoma of the body using statistical image analysis. <i>Annals of Nuclear Medicine</i> , 2014, 28, 950-960.	2.2	10
72	Screening of promising chemotherapeutic candidates from plants against human adult T-cell leukemia/lymphoma (IV): phenanthroindolizidine alkaloids from <i>Tylophora tanakae</i> leaves. <i>Journal of Natural Medicines</i> , 2015, 69, 397-401.	2.3	10

#	ARTICLE	IF	CITATIONS
73	FoxP3 ⁺ positive T cell lymphoma arising in non-HTLV1 carrier: clinicopathological analysis of 11 cases of PTCL ⁺ NOS and 2 cases of mycosis fungoides. <i>Histopathology</i> , 2016, 68, 1099-1108.	2.9	10
74	Is Zidovudine and Interferon- α the Gold Standard for Adult T-Cell Leukemia-Lymphoma?. <i>Journal of Clinical Oncology</i> , 2010, 28, e765-e765.	1.6	9
75	Safety and pharmacokinetic evaluation of repeated intravenous administration of palonosetron 0.75 μ g in patients receiving highly or moderately emetogenic chemotherapy. <i>Supportive Care in Cancer</i> , 2014, 22, 1959-1964.	2.2	9
76	Cell death induced by dorsomorphin in adult T-cell leukemia/lymphoma is AMPK ⁺ independent. <i>FEBS Journal</i> , 2020, 287, 4005-4015.	4.7	9
77	DS-3201, a Potent EZH1/2 Dual Inhibitor, Demonstrates Antitumor Activity Against Non-Hodgkin Lymphoma (NHL) Regardless of EZH2 Mutation. <i>Blood</i> , 2018, 132, 2217-2217.	1.4	9
78	A Global Phase 2 Study of Valemetostat Tosylate (Valemetostat) in Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL), Including R/R Adult T-Cell Leukemia/Lymphoma (ATL) - Valentine-PTCL01. <i>Blood</i> , 2021, 138, 2533-2533.	1.4	9
79	BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: a first-in-human phase-I study. <i>BMC Cancer</i> , 2017, 17, 89.	2.6	8
80	Development of reference material with assigned value for human T-cell leukemia virus type 1 quantitative PCR in Japan. <i>Microbiology and Immunology</i> , 2018, 62, 673-676.	1.4	8
81	Possibility of a risk-adapted treatment strategy for untreated aggressive adult T-cell leukaemia-lymphoma (<sc>ATL</sc>) based on the <sc>ATL</sc> prognostic index: a supplementary analysis of the <sc>JCOG</sc>9801. <i>British Journal of Haematology</i> , 2019, 186, 440-447.	2.5	8
82	Multicenter Phase II Study of KW-0761, a Defucosylated Anti-CCR4 Antibody, In Relapsed Patients with Adult T-Cell Leukemia-Lymphoma (ATL). <i>Blood</i> , 2010, 116, 285-285.	1.4	8
83	Expression of the intestinal T-lymphocyte-associated-molecule recognized by the HML-1 antibody on mononuclear cells from HTLV-I-infected subjects. <i>American Journal of Hematology</i> , 1995, 50, 1-8.	4.1	7
84	Screening of promising chemotherapeutic candidates from plants against human adult T-cell leukemia/lymphoma (V): coumarins and alkaloids from <i>Boenninghausenia japonica</i> and <i>Ruta graveolens</i> . <i>Journal of Natural Medicines</i> , 2017, 71, 170-180.	2.3	7
85	SRT1720 induces SIRT1 ⁺ independent cell death in adult T-cell leukemia/lymphoma. <i>FEBS Journal</i> , 2022, 289, 3477-3488.	4.7	7
86	Prediction of the risk for graft <i>versus</i> host disease after allogeneic hematopoietic stem cell transplantation in patients treated with mogamulizumab. <i>Leukemia and Lymphoma</i> , 2022, 63, 1701-1707.	1.3	7
87	Significance of Elevated Levels of Soluble Factors in the Cerebrospinal Fluid in Patients with, Adult T-cell Leukemia. <i>Leukemia and Lymphoma</i> , 1995, 19, 437-445.	1.3	6
88	Interferon- γ and zidovudine for relapsed/refractory adult T cell leukemia/lymphoma: case reports of Japanese patients. <i>International Journal of Hematology</i> , 2010, 92, 762-764.	1.6	6
89	First reported case of hemoglobin lancing in Asia detected by false low oxygen saturation on pulse oximetry. <i>International Journal of Hematology</i> , 2012, 95, 731-732.	1.6	6
90	A survivin-responsive, conditionally replicating adenovirus induces potent cytotoxic effects in adult T-cell leukemia/lymphoma. <i>BMC Cancer</i> , 2019, 19, 516.	2.6	6

#	ARTICLE	IF	CITATIONS
91	Diagnosis and management of adult T-cell leukemia/lymphoma. <i>Seminars in Hematology</i> , 2021, 58, 114-122.	3.4	6
92	The small molecule STF-62247 induces apoptotic and autophagic cell death in leukemic cells. <i>Oncotarget</i> , 2018, 9, 27645-27655.	1.8	6
93	Aggressive NK cell leukaemia after splenectomy: association with CD95-resistant memory T-cell proliferation and recalcitrant clinical course of haemophagocytic syndrome. <i>European Journal of Haematology</i> , 2008, 81, 236-241.	2.2	5
94	CCR1 Inhibition Impairs Osteoclast Activity and Interaction with Myeloma Cells.. <i>Blood</i> , 2006, 108, 3494-3494.	1.4	5
95	Elevated soluble CD4 levels in the cerebrospinal fluid in patients with adult T-cell leukemia. <i>American Journal of Hematology</i> , 1994, 46, 95-100.	4.1	4
96	FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma. <i>British Journal of Haematology</i> , 2006, 132, 698-704.	2.5	4
97	Pre- and posttransplant use of mogamulizumab in patients with aggressive adult T-cell leukemia-lymphoma: A statement from key opinion leaders in Japan. <i>Advances in Cell and Gene Therapy</i> , 2018, 1, e5.	0.9	4
98	Treatment of aggressive adult T-cell leukemia/lymphoma: a retrospective study in a hospital located in HTLV-1 highly endemic area. <i>International Journal of Hematology</i> , 2020, 111, 234-240.	1.6	4
99	Interferon-alpha and antiretroviral agents: a treatment option for adult T-cell leukemia/lymphoma. , 2011, 47, 615.		4
100	Pivotal Phase 2 Study of the EZH1 and EZH2 Inhibitor Valemetostat Tosylate (DS-3201b) in Patients with Relapsed or Refractory Adult T-Cell Leukemia/Lymphoma. <i>Blood</i> , 2021, 138, 303-303.	1.4	4
101	Hematologic Malignancies (HM)-Screen-Japan 01: A Mutation Profiling Multicenter Study on Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 4457-4457.	1.4	4
102	Screening of Promising Chemotherapeutic Candidates from Plants against Human Adult T-Cell Leukemia/Lymphoma (VII): Active Principles from <i>Thuja occidentalis</i> L.. <i>Molecules</i> , 2021, 26, 7619.	3.8	4
103	Q575E: A novel recurrent gain-of-function mutation in patients with adult T-cell leukemia/lymphoma. <i>European Journal of Haematology</i> , 2021, 106, 221-229.	2.2	3
104	Cardiac Involvement of Adult T Cell Leukemia/Lymphoma. <i>Internal Medicine</i> , 2022, 61, 1055-1057.	0.7	3
105	The Role of B Cell-Activating Factor (BAFF) in the Biology of Multiple Myeloma (MM).. <i>Blood</i> , 2005, 106, 3380-3380.	1.4	3
106	Characterization of Long-Term Survivors and a Predictive Model for Aggressive Adult T-Cell Leukemia-Lymphoma (ATL): An Ancillary Study by the Japan Clinical Oncology Group, JCOG0902A. <i>Blood</i> , 2011, 118, 881-881.	1.4	3
107	Clinical significance of the immunoglobulin G heavy-chain repertoire in peripheral blood mononuclear cells of adult T-cell leukaemia-lymphoma patients receiving mogamulizumab. <i>British Journal of Haematology</i> , 2021, 196, 629.	2.5	3
108	Screening of Promising Chemotherapeutic Candidates from Plants against Human Adult T-Cell Leukemia/Lymphoma (VI): Cardenolides from <i>Asclepias curassavica</i> . <i>Biological and Pharmaceutical Bulletin</i> , 2020, 43, 1609-1614.	1.4	3

#	ARTICLE	IF	CITATIONS
109	Long-term follow-up of patients with ATL after autologous stem cell transplantation. Bone Marrow Transplantation, 2022, 57, 323-325.	2.4	3
110	Novel Anti-CD70 Antibody Drug Conjugate for the Treatment of Adult T-Cell Leukemia (ATL). Anticancer Research, 2020, 40, 4471-4479.	1.1	2
111	Clinical and cytopathological characteristics of HTLV-1 ⁺ hodgkin lymphoma. Cancer Medicine, 2020, 9, 5788-5797.	2.8	2
112	Serotonin Receptor Antagonists Have an In Vitro and In Vivo Anti-Myeloma Effect That Is Mainly Mediated by Caspase Dependent Apoptosis.. Blood, 2006, 108, 2597-2597.	1.4	2
113	Reply to J.J. Castillo et al. Journal of Clinical Oncology, 2012, 30, 3561-3561.	1.6	1
114	Polypharmacy in Elderly Cancer Patients. Annals of Oncology, 2014, 25, v100.	1.2	1
115	A Novel Recurrent Gain-of-Function Mutation of Rltpr Q575E in Adult T Cell Leukemia/Lymphoma. Blood, 2019, 134, 1489-1489.	1.4	1
116	Mitochondria and Caspase-Independent Cell-Death Triggered by GCS-100, a Novel Carbohydrate-Based Therapeutic in Multiple Myeloma (MM) Cells.. Blood, 2004, 104, 2456-2456.	1.4	1
117	Combination of the mTOR Inhibitor Rapamycin and Revlimid [®] (CC-5013) Has Synergistic Activity in Multiple Myeloma (MM).. Blood, 2004, 104, 1492-1492.	1.4	1
118	TGF- β 2 Receptor I Kinase Inhibitor Downregulates Cytokine Secretion and Multiple Myeloma Cell Growth in the Bone Marrow Microenvironment.. Blood, 2004, 104, 2355-2355.	1.4	1
119	Endothelial Cells Induce Multiple Myeloma Cell Proliferation Protect Against Conventional and Novel Therapies.. Blood, 2004, 104, 2354-2354.	1.4	1
120	The Tyrosine Kinase Inhibitor Adaphostin (NSC 680410), but Not Imatinib Mesylate, Inhibits Survival and Src Tyrosine Kinase Family- Triggered Signaling Pathways of MM Cells.. Blood, 2004, 104, 3352-3352.	1.4	1
121	Cladribine Treatment in Two-Hour Intravenous Infusion for Previously-Treated Low Grade B-Cell Lymphoma : A Pilot Study. Journal of Clinical and Experimental Hematopathology: JCEH, 2009, 49, 69-75.	0.8	1
122	Prognostic index for chronic and smoldering types adult T-cell leukemia/lymphoma.. Journal of Clinical Oncology, 2015, 33, 8522-8522.	1.6	1
123	Genomic Analysis Focusing on RUNX1-RUNX1T1 in Japanese Patients with AML: HM-Screen-Japan 01. Blood, 2021, 138, 4464-4464.	1.4	1
124	Clinical Significance of FLT3 Mutations in a Comprehensive NGS Multicenter Study of AML: HM-Screen-Japan 01. Blood, 2021, 138, 2313-2313.	1.4	1
125	Is Watch and Wait Still Standard for Indolent AtL?. Annals of Oncology, 2014, 25, v26.	1.2	0
126	Febrile Neutropenia(Fn)And D-Index. Annals of Oncology, 2014, 25, v42.	1.2	0

#	ARTICLE	IF	CITATIONS
127	Treatment of Indolent Adult T-cell Leukemia/Lymphoma (ATL). , 2017, , 117-124.		0
128	The difficulty in establishing clinical evidence of extremely-rare hematological malignancies. Annals of Oncology, 2018, 29, vii41.	1.2	0
129	Septic vasculitis induces cutaneous involvement of adult Tâ€cell leukemia/lymphoma. International Journal of Dermatology, 2020, 59, e298-e300.	1.0	0
130	Honokiol Overcomes Conventional Drug Resistance in Human Multiple Myeloma.. Blood, 2004, 104, 1488-1488.	1.4	0
131	Atiprimod (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) Inhibits Myeloma in Vivo.. Blood, 2004, 104, 2401-2401.	1.4	0
132	Targeting IKK Inhibits Multiple Myeloma (MM) Cell Growth in the Bone Marrow Microenvironment.. Blood, 2004, 104, 2351-2351.	1.4	0
133	SDX-101 Is Cytotoxic and Overcomes Drug Resistance in Multiple Myeloma.. Blood, 2004, 104, 3466-3466.	1.4	0
134	VEGF Upregulates Mcl-1 Expression and Protects Multiple Myeloma Cells Against Starvation Induced-Apoptosis.. Blood, 2004, 104, 631-631.	1.4	0
135	Bortezomib Targets Multiple Myeloma Endothelial Cells.. Blood, 2004, 104, 4903-4903.	1.4	0
136	Anti-Tumor Activity of a Novel Immunosuppressant FTY720 in Multiple Myeloma.. Blood, 2004, 104, 3456-3456.	1.4	0
137	P38 MAPK Inhibition Enhances PS-341 (bortezomib)-Induced Cytotoxicity Against Multiple Myeloma Cells.. Blood, 2004, 104, 3348-3348.	1.4	0
138	In Vitro Activity of a Novel Small Molecule Cyclin Dependent Kinase Inhibitor, CYC202 (seliciclib or) Tj ETQqO O O rgBT /Overlock 10 Tf 50	1.4	0
139	JS-K, a GST-Activated Nitric Oxide Generator, Induces Apoptosis and Overcomes In Vitro Drug Resistance in Multiple Myeloma Cells.. Blood, 2005, 106, 1593-1593.	1.4	0
140	Up-Regulation of c-Jun contributes to the Induction of Apoptosis by Adaphostin in Human Multiple Myeloma Cells.. Blood, 2005, 106, 1585-1585.	1.4	0
141	Didox Induced Apoptosis Occurs by Inhibiting DNA Synthesis and Repair Via Down-Regulation of Ribonucleotide Reductase M1 in Multiple Myeloma (MM).. Blood, 2005, 106, 5153-5153.	1.4	0
142	MLN3897, a Novel CCR1 Antagonist, Inhibits Osteoclastogenesis by Blocking Early ERK Activation.. Blood, 2006, 108, 1636-1636.	1.4	0
143	Akt Inhibitor Perifosine-Induced Cytotoxicity Is Associated with Significant Downregulation of Survivin in Human Multiple Myeloma (MM) Cells.. Blood, 2006, 108, 3410-3410.	1.4	0
144	The Small-Molecule VEGF-Receptor Inhibitor Pazopanib (GW786034B) Targets Both Tumor and Endothelial Cells in Multiple Myeloma.. Blood, 2006, 108, 5003-5003.	1.4	0

#	ARTICLE	IF	CITATIONS
145	BIRB796 Inhibits p38 MAPK/Hsp27 Pathway and Enhances Cytotoxicity Triggered by Bortezomib, Hsp90 Inhibitor, and Dexamethasone in Multiple Myeloma.. Blood, 2006, 108, 3440-3440.	1.4	0
146	A Promising Therapeutic Implication of a Novel Bcl-2 Family Inhibitor ABT-737 for Adult T-Cell Leukemia/Lymphoma.. Blood, 2008, 112, 1584-1584.	1.4	0
147	Targeting Bcl-2 Family Proteins in Adult T-Cell Leukemia/Lymphoma: In Vitro and In Vivo Effects of a Novel Bcl-2 Family Inhibitor ABT-737.. Blood, 2009, 114, 1685-1685.	1.4	0
148	Current Clinico-Epidemiological Characteristics of Adult T-Cell Leukemia-Lymphoma (ATL) Based on the 11th Nationwide Survey in Japan. Blood, 2015, 126, 5034-5034.	1.4	0
149	Treatment and Prognosis in Patients with Adult T-Cell Leukemia-Lymphoma (ATL): A Nationwide Survey in Japan. Blood, 2016, 128, 5936-5936.	1.4	0
150	Impact of Chromosomal Abnormalities in Acute and Lymphoma Types Adult T-Cell Leukemia-Lymphoma. Blood, 2016, 128, 4123-4123.	1.4	0
151	OPEC/Mpec for Adult T-Cell Leukemia/Lymphoma: A Single-Institution Study. Blood, 2016, 128, 1828-1828.	1.4	0
152	V. Adult T-cell Leukemia: Diagnosis and Treatment. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 1397-1403.	0.0	0
153	Possibility of a Risk-Adapted Treatment Strategy for Untreated Aggressive Adult T-Cell Leukemia-Lymphoma (ATL) Based on the ATL Prognostic Index: A Supplementary Analysis of the JCOG9801 Study. Blood, 2018, 132, 1645-1645.	1.4	0
154	Properties and Distribution of IDH-1/2 Mutations in Acute Myeloid Leukemia By the Comprehensive Genomic Analysis. Blood, 2021, 138, 4447-4447.	1.4	0
155	Genomic Analysis of <i>NPM1</i> Mutation and <i>KMT2A</i> (<i>MLL</i>)-Rearrangement/Amplification in Japanese Patients with Acute Myeloid Leukemia: Hematologic Malignancies (HM)-Screen-Japan 01. Blood, 2021, 138, 4460-4460.	1.4	0
156	Genetic Features of AML with MLL-Rearrangement and NPM1 Mutation: An Interim-Analysis of HM-Screen-Japan 01. Blood, 2020, 136, 35-36.	1.4	0
157	Whole-Genome Analysis of Adult T-Cell Leukemia/Lymphoma. Blood, 2020, 136, 29-30.	1.4	0